Assessment of Symptom-Related Cytokines in Lung and Gastrointestinal (GI) Cancer Patients

Learn more about:
Related Clinical Trial
CRTE7A2-01 TCR-T Cell for HPV-16 Positive Advanced Cervical, Anal, or Head and Neck Cancers Assessment of Patients’ Quality of Sexual Life After Anal Cancer Treatment Neoadjuvant PD-1 Blockade Combined With Chemotherapy Followed by Concurrent Immunoradiotherapy for Locally Advanced Anal Canal Squamous Carcinoma Patients Pencil Beam Proton Therapy for Recurrences in Anal Cancer Patients Previously Treated With Radiotherapy (DACG 5) Hyperthermia Enhanced Re-irradiation of Loco-regional Recurrent Tumors Detecting HPV DNA in Anal and Cervical Cancers ANCA II – Quality of Life and Functional Outcome in Patients With Anal Cancer RTX-321 Monotherapy in Patients With HPV 16+ Tumors Anal Injury Screening for High Risk HPV M7824 in Subjects With HPV Associated Malignancies Multimodal Monitoring of Radiotherapy Response in Squamous Cell Cancer Avastin/[18-F]-5-fluorouracil PET/CT Imaging Feasibility Project Assessment of Health Related Quality of Life in Patients Treated for Rectal Cancer Octreotide in Preventing or Reducing Diarrhea in Patients Receiving Chemoradiotherapy for Anal or Rectal Cancer Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies Function Following Laser for Anal Intraepithelial Neoplasia (FLAN) A Message Framing Intervention for Increasing Parental Acceptance of Human Papillomavirus Vaccination Anal Sphincter Prosthesis in Treating Patients Who Are Undergoing Surgery for Anal or Rectal Cancer Phase 2 Study of ADXS11-001 in Subjects With Carcinoma of the Anorectal Canal Pilot Study to Determine the Safety and Efficacy of Gardasil Against the Human Papilloma Virus (HPV) in HIV-infected Men Assessment of Symptom-Related Cytokines in Lung and Gastrointestinal (GI) Cancer Patients Identification of Predictive Factors for Physiological Hypermetabolism of the Anal Canal in 18F-FDG PET / CT Early Rectal Cancer: Endoscopic Submucosal Dissection or Transanal Endoscopic Microsurgery? Drainage Seton With Flap Versus EAS Preserving Seton in Treatment of Transsphincteric Anal Fistula HPV-SAVE: 9-Valent HPV Vaccine for High-Grade Anal Dysplasia Radiation Dosimetry Study Comparing 2 Different Patient Setups in Anal/Rectal Cancer Patients Comparing Two Types of Swabs in Collecting Cell Samples for Anal Pap Tests and Human Papillomavirus Tests in Men Who Have Sex With Men The HPV-SAVE Study Team: HPV Screening and Vaccine Evaluation in Men Who Have Sex With Men High-Resolution Anoscopy Perceived Discomfort Study Infrared Coagulator Ablation or Observation in Preventing Anal Cancer in HIV-Positive Patients With Anal Neoplasia Image Fusion PET, CT and 3D-ultrasound Examinations Hybrid Capture 2 Human Papiloma Virus (HPV) High-Risk Anal DNA Test ART: Anal Squamous Cell Carcinoma: Investigation of Functional Imaging During chemoRadioTherapy Anal HPV Tests in Screening for Cell Changes in the Anus in Patients With HIV Molecular Genetic and Pathological Studies of Anal Tumors Intensity-Modulated Radiation Therapy, Fluorouracil, and Mitomycin C in Treating Patients With Invasive Anal Cancer Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer QOL & Functional Outcomes After Combined Modality Tx for Anal CA: Comparison of Conventional vs IMRT A Study of mDCF in Combination or Not With Atezolizumab in Advanced Squamous Cell Anal Carcinoma Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer Infrared Coagulation in Preventing Anal Cancer in Patients With HIV Who Have Anal Neoplasia Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer Topical MTS-01 for Dermatitis During Radiation and Chemotherapy for Anal Cancer Radiochemotherapy +/- Durvalumab for Locally-advanced Anal Carcinoma. A Multicenter, Randomized, Phase II Trial of the German Anal Cancer Study Group Intrafractional Vaginal Dilation in Anal Cancer Patients Undergoing Pelvic Radiotherapy Screening for HIV-Associated Anal Cancer Combined Modality Therapy for Patients With With HIV and Stage I, Stage II, or Stage III Anal Cancer Cetuximab, Cisplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Anal Cancer Study of IMRT Radiotherapy Concurrent Chemothrerapy for Anal Cancer A Prospective, Open-Label, Multi-center Comparison of Lymphoseek Identified Lymph Nodes and Clinically Identified Lymph Nodes of Subjects With Known Cancer of the Anus Prospective Observational Trial to Evaluate Quality of Life After Definitive Chemoradiation in Patients With Anal Cancer (LANACARE) Radiation Therapy Plus Fluorouracil With or Without Additional Chemotherapy in Treating Patients With Primary Anal Cancer Prospective Cohort on Quality of Sexual Life Among Men Who Have Sex With Men Treated for Anal Cancer With Concurrent Chemotherapy and Intensity-modulated Radiotherapy Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer SGN-00101 in Preventing Anal Cancer in Patients With HIV Who Have Anal Neoplasia Anal Cancer Radiotherapy Study Radiation Therapy, Mitomycin, and Either Fluorouracil or Cisplatin in Treating Patients With Locally Advanced Anal Cancer Radiation Therapy, Cisplatin, Fluorouracil, and Cetuximab in Treating Patients With Locally Advanced Anal Cancer Individual Following in Anal Cancer With PET/CT Anal Cancer Screening Study The Prevent Anal Cancer Self-Swab Study Shared Decision Making With Anal Cancer Patients on Radiation Dose Predictive Value of FMISO-PET, FDG-PET-CT, DWI-MRI and DCE-MRI Scans for Patients With Anal Cancer Receiving Radiotherapy +/- Chemotherapy Quality of Life in Patients With Anal Cancer Functional Outcomes Following Anal Cancer Treatment Pembrolizumab in Refractory Metastatic Anal Cancer A Phase I/II Evaluation of ADXS11-001, Mitomycin, 5-fluorouracil (5-FU) and IMRT for Anal Cancer

Brief Title

Assessment of Symptom-Related Cytokines in Lung and Gastrointestinal (GI) Cancer Patients

Official Title

Feasibility Study of the Assessment of Symptom-Related Cytokines in Lung and GI Cancer Patients Undergoing Chemoradiation Therapy

Brief Summary

      Primary Objectives:

        -  To determine the feasibility of a study that would describe changes of certain
           circulating inflammatory cytokines (interleukin-1, 6, 8, 10, 12, and tumor necrosis
           factor-alpha [TNF] and symptoms related to chemoradiation therapy (pre-therapy, during
           therapy and up to 3 months post-therapy) among patients with lung, esophageal, gastric,
           colorectal and anal cancer.

        -  To determine the feasibility of studying neurocognitive function in patients with
           non-small cell lung cancer (NSCLC) at presentation and during chemoradiation therapy to
           determine the prevalence, severity, and pattern of cognitive symptoms.

Detailed Description

      One of the ways to learn about the symptoms of chemoradiation therapy is by looking at how
      certain proteins called cytokines (found in the blood) change during therapy. Another way is
      to look at how thinking and memory may be changed because of treatment.

      Before therapy starts, you will be asked to complete several questionnaires during a visit to
      the Radiation Oncology clinic at M. D. Anderson. These questionnaires measure physical and
      emotional symptoms. These questionnaires should take about 30 minutes to finish. Lung cancer
      patients will also complete some cognitive (mental) questionnaires. During this visit, the
      research nurse will teach you how to use the telephone system for measuring symptoms. You
      will tell the system the most convenient times for the telephone calls. The date of the call
      will be at the same or close to the date of your weekly clinic visit.

      Before you begin your chemoradiation treatments, you will have a sample of blood drawn
      (around 2½ tablespoons). The sample of blood will be used to measure levels of cytokines in
      your blood pre treatment.

      You will have about 2½ tablespoons of blood drawn again when you start chemoradiation, and
      then once a week while you are receiving treatment. These cytokines may be related to
      symptoms experienced while having treatment for cancer. These blood tests are being done to
      study the levels of cytokines in your blood during, and after treatment for cancer.

      Symptoms will be monitored weekly using an interactive voice response telephone system.
      During chemoradiation, the automated telephone system will call you once a week to ask you to
      rate your symptoms and how much the symptoms interfere in your daily life. The information
      collected by these calls is only being used for this research study.

      At the end of the chemoradiation, lung cancer patients will again be given questionnaires to
      measure cognitive symptoms.

      For lung cancer patients who are post-chemotherapy, your symptoms will be monitored weekly
      for 3 months after therapy using the interactive voice response telephone system. For
      esophageal, gastric, colorectal, and anal patients who are post-therapy, your symptoms will
      be monitored weekly for 6 weeks after therapy using the interactive voice response telephone
      system. About 30 days after chemoradiation, you will have 2½ tablespoons of blood drawn at
      your regularly scheduled clinic visit. If you are not scheduled for a 3 month clinic visit,
      we will contact your local physician for blood lab results.

      This is an investigational study. About 225 evaluable patients will take part in this study.
      All will be enrolled at M. D. Anderson.

Study Type


Primary Outcome

Patient Symptom Assessment (Questionnaire)


Anal Cancer



Study Arms / Comparison Groups

 Symptom-Related Cytokines Questionnaire


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

November 2002

Completion Date

July 2010

Primary Completion Date

July 2010

Eligibility Criteria

        Inclusion Criteria:

          1. Patients scheduled for chemoradiation therapy at MDACC.

          2. Adults > 18 years of age.

          3. Diagnosis of lung, esophageal, gastric, colorectal, or anal cancer.

          4. English-speaking.

          5. Lives in the United States.

          6. Adequate vision and hearing to use the IVR system.

          7. Provides written informed consent.

        Exclusion Criteria:

          1. Patients with a current diagnosis of psychosis or dementia.

          2. Patients who are unable to complete the assessment measures or refuse to participate.




18 Years - N/A

Accepts Healthy Volunteers



Xin Shelley Wang, MD, , 

Location Countries

United States

Location Countries

United States

Administrative Informations



Organization ID


Responsible Party


Study Sponsor

M.D. Anderson Cancer Center


 National Cancer Institute (NCI)

Study Sponsor

Xin Shelley Wang, MD, Principal Investigator, M.D. Anderson Cancer Center

Verification Date

July 2012